Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity-Reference-Cited by-同舟云学术

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity

Published:2017-04 Issue: Volume:75 Page:24-32
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Gutzmer Ralf,Koop Anika,Meier Friedegund,Hassel Jessica C.,Terheyden Patrick,Zimmer Lisa,Heinzerling Lucie,Ugurel Selma,Pföhler Claudia,Gesierich Anja,Livingstone Elisabeth,Satzger Imke,Kähler Katharina C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Nivolumab safety in patients with advanced melanoma who have progressed on or after ipilimumab: a single-arm, open-label, multicenter, phase II study (checkmate 172);Ascierto;J Clin Oncol,2016

2. AJCC melanoma staging and classification;Balch;J Clin Oncol,2009

3. Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment;Bender;Ann Oncol,2016

4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015

5. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy;Eigentler;Cancer Treat Rev,2016

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry;Targeted Oncology;2024-08-24

2. Peripheral nervous system immune-related adverse events due to checkpoint inhibition;Nature Reviews Neurology;2024-08-09

3. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease;European Journal of Cancer;2024-08

4. Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery;International Immunopharmacology;2024-08

5. Immune Checkpoint Inhibitor-Induced Psoriasis;Dermatologic Clinics;2024-07